CBD

IMPORTANT: It is always best to consult with a clinical pharmacist, such as myself, before taking or using any CBD product. I provide a full clinical assessment of your current medications and conditions as they relate to CBD. My products are pharmacist-formulated, organic CBD products of the highest quality grown right here in Florida. After your purchase, we remain connected for continued monitoring and guidance as you begin and continue your regimen

CBD BASIC FACTS

  • CBD differs from THC and does not cause psychoactive effects or a “high.”
  • CBD is legal as long as the product contains no more than 0.3 % THC.
  • CBD products will not lead to a positive drug test.
  • Our bodies have an endocannabinoid system consisting of CB1 and CB2 receptors.
    • These receptors are being studied as it seems they can regulate: sleep, mood, pain, inflammation, and skin issues.

PRODUCTS

  • Pharmacist-Formulated
  • Organic
  • Top-Quality
  • Florida Grown
  • Pesticide and Harsh Chemical-Free
  • Gluten-Free
  • Non-GMO
  • Made with Good Manufacturing Practices (GMP)

CBD Broad Spectrum Drops with MCT Oil

1000 mg per Bottle

Fruit Punch Flavor

$85

To Order Contact Heather at pharmie@cox.net


Vegan CBD Gummies

25mg CBD per Gummie

30 Count Bottle

$65

To Order Contact Heather at pharmie@cox.net


CBD Intensive Relief Rub with Emu Oil

500 mg of CBD per Pump Container

$65

To Order Contact Heather at pharmie@cox.net


CBD RESEARCH AND INFORMATION

ANXIETY

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess anxiolytic effects.  (De Gregorio et al., 2019). It has been thought that CBD acts within the body very similarly to the anti-anxiety medication Buspar (buspirone). Activation of the CB1 receptor activation may play a limited role in reducing anxiety, stress, and fear as well. A review concluded that “existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and posttraumatic disorder when administered acutely (Blessings et al., 2015).”

In 2011, a study was performed using a public speaking assignment to test whether anxiety was relieved with CBD. For this research 24 never-treated patients with Social Anxiety Disorder (SAD) were randomly assigned to receive either CBD or placebo in a double-blind randomized design. “Pretreatment with CBD significantly reduced anxiety, cognitive impairment, and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech. The placebo group presented higher anxiety, cognitive impairment, discomfort, and alert levels when compared with the control group (Bergamaschi et al., 2011).”

In 2019, two studies researching daily dosing of CBD found that anxiety levels improved after taking CBD in an ongoing regimen. Most patients saw improvement in anxiety symptoms. Results showed that CBD given to teenagers with SAD for a 4-week period reduced the level of anxiety symptoms (Masataka, 2019). Also, in adult patients, anxiety decreased over the first month of daily CBD treatment and remained stabilized for the 3- month duration of the study (Shannon et al, 2019). CBD was well-tolerated in both studies. It is important to note that a small number of patients experienced increased anxiety or no effect.

  • Important TakeAways:
    • CBD appeared to have a positive effect on decreasing anxiety in the above studies.
    • The dosing of CBD in the above-mentioned studies varied. Thus starting low and going slow is the best course of action.
    • In all of the above studies, CBD appeared to be generally well tolerated.
    • More studies need to be conducted to determine proper dosing and to identify the ideal patient for CBD treatment.

References:

Bergamaschi, M., Queiroz, R., Chagas, M. et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacol 361219–1226 (2011). https://doi.org/10.1038/npp.2011.6

Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007/s13311-015-0387-1

De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160(1):136-150. doi:10.1097/j.pain.0000000000001386

Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019;10:2466. Published 2019 Nov 8. doi:10.3389/fpsyg.2019.02466

Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi:10.7812/TPP/18-041

SLEEP

In a recent 2019 study, 72 adults with anxiety and poor sleep were given 25 mg of CBD for 3 months. Those with predominant anxiety took the dose in the morning, and the individuals complaining more about sleep issues took the dose in the evening. The participants completed anxiety and sleep assessments at the start of the study and at the first-month follow-up.

In the first month’s assessment, 79 percent of the people showed decreased anxiety. Sixty-six percent (66%) of the participants indicated improved sleep, which indicated less trouble sleeping. This study suggests that CBD decreased sleep difficulties in many of the participants. But while the decrease in anxiety symptoms remained steady for the duration of the study, the sleep scores fluctuated over time (Shannon et al., 2019)

References:

Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi:10.7812/TPP/18-041

PAIN / INFLAMMATION

NEUROPATHIC (NERVE) PAIN: CB1, CB2, and TRPV1 receptors are upregulated when nerve injury is present. This may explain why, in a recent 2018 review, CBD was shown to improve nerve pain without any development of tolerance, physical withdrawal, and other CNS side effects. In subjects with diabetic neuropathy (nerve pain), results seem to show that earlier treatment with CBD showed greater effects, then when CBD was given after chronic, long-term neuropathy (Vuckovic et al., 2018). CBD stimulates adenosine A2A and PPAR gamma receptors and thus may be the reason for decreased inflammation and pain.

Reference:

Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018;9:1259. Published 2018 Nov 13. doi:10.3389/fphar.2018.01259

ARTHRITIS PAIN: Topical CBD was shown to significantly reduce joint swelling, pain, immune cell infiltration, and thickening of the synovial membrane in a dose-dependent manner in subjects with arthritis using the gel for 4 days. No adverse effects were noted. Since CBD is not very water-soluble and has poor oral bioavailability, topical CBD is a good alternative to oral CBD in some cases. Topical CBD avoids stomach digestion, liver metabolism (first-pass metabolism) and can provide more constant plasma levels (Hammell et al., 2016). CBD stimulates adenosine A2A and PPAR gamma receptors and thus may be the reason for decreased inflammation and pain.

Reference:

Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936-948. doi:10.1002/ejp.818

SKIN ISSUES

A recent 2019 retrospective study of 20 individuals with either psoriasis or atopic dermatitis with resulting scars used a topical CBD ointment twice daily for 3 months. The results showed that the CBD ointment significantly improved the skin symptoms, increased hydration of skin, and increased elasticity in ALL patients. No irritant or allergic reactions were documented during the study period (Palmieri et al., 2019). CBD stimulates adenosine A2A and PPAR gamma receptors and thus may be the reason for decreased inflammation.

Reference:

Palmieri B, Laurino C, Vadalà M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter. 2019;170(2):e93-e99. doi:10.7417/CT.2019.2116